Every cell in your body runs on a molecule most people have never heard of. NAD+ (nicotinamide adenine dinucleotide) is the coenzyme that lets your mitochondria turn food into usable energy, and it doubles as the fuel for the enzymes that repair damaged DNA and regulate how your cells age. It is not a vitamin, not a hormone, and not something you can meaningfully eat — your body builds it from vitamin B3 precursors, recycles it thousands of times a day, and consumes it constantly.
Over the past decade NAD+ has become one of the most heavily marketed ideas in longevity. Some of the excitement is well-founded: the biology is real, the age-related decline is measurable, and the precursor supplements genuinely do raise NAD+ in human blood. But the gap between "raises a biomarker" and "makes you healthier" is where most of the marketing quietly lives. This article walks through what NAD+ actually does, why it falls with age, what the human trials found, and how to think about it without either dismissing it or overpaying for it.
Quick Facts
- NAD+ is a coenzyme required for mitochondrial energy production and for the sirtuin and PARP enzymes that handle DNA repair and cellular stress response.
- NAD+ concentrations fall with age in human skin, muscle, liver and brain tissue — in some tissues by more than half between young adulthood and older age.
- Oral precursors — nicotinamide riboside (NR), nicotinamide mononucleotide (NMN), niacin and nicotinamide — reliably raise NAD+ in blood, typically by 40–150% at gram-level doses.
- Raising blood NAD+ has proven far easier than producing clinical benefit: most trials in healthy adults show biomarker changes without meaningful functional improvement.
- The clearest documented benefits are in specific clinical populations — notably niacin in adult-onset mitochondrial myopathy — not in healthy people looking for more energy.
What NAD+ Actually Does in Your Cells
NAD+ has two jobs, and they compete with each other.
Job one: shuttling electrons
The first job is metabolic. When your cells break down glucose, fat or amino acids, the energy released is captured as electrons, and NAD+ is the molecule that carries them. It picks up an electron pair to become NADH, delivers it to the electron transport chain inside your mitochondria, and converts back to NAD+ ready for another round. This cycle happens on a scale that is hard to intuit — your body turns over roughly its own body weight in ATP each day, and NAD+ is recycled continuously to make that possible. In this role NAD+ is not consumed; it is borrowed and returned.
Job two: fuelling the repair and signalling enzymes
The second job is where NAD+ actually gets used up. Three families of enzymes cleave NAD+ and consume it permanently: sirtuins (which regulate gene expression, mitochondrial biogenesis and stress responses), PARPs (which detect and repair DNA strand breaks), and CD38 (an immune-associated enzyme that degrades NAD+ at a high rate). Every DNA repair event, every sirtuin-mediated signalling step, draws down the pool. This is why chronic DNA damage, inflammation and metabolic stress are all NAD+-expensive states — and why the same molecule sits at the junction of energy metabolism and biological ageing.
Your cells do not store NAD+ in any significant quantity. They rebuild it constantly through the salvage pathway, recycling nicotinamide released by those consuming enzymes back into fresh NAD+. Supply and demand have to balance essentially in real time.
Why NAD+ Declines With Age
The observation that NAD+ falls with age is one of the more reproducible findings in ageing biology. A frequently cited human tissue study found NAD+ in non-sun-exposed skin dropped substantially across a range of donors aged from infancy to 77, tracking alongside rising markers of oxidative stress. Similar declines have been documented in muscle, liver and brain across multiple species.
The mechanism appears to be less about failing production and more about rising consumption. Work in mice identified CD38 — an NAD+-degrading enzyme expressed on immune cells — as a primary driver: CD38 expression increases markedly with age, and blocking it restores NAD+ and mitochondrial function. Accumulating senescent cells appear to recruit and activate CD38-expressing macrophages, creating a feedback loop in which the inflammatory tissue environment of ageing directly drains the NAD+ pool. Chronic DNA damage adds to this by keeping PARP enzymes persistently active.
An important caveat that rarely makes it into marketing copy: the human tissue data are much sparser than the rodent data, and whole-blood NAD+ is not a reliable proxy for what is happening inside muscle, liver or brain. A 2025 review of the clinical literature made this point directly — the field still lacks good tissue-level measurements in humans, which is one reason trial results have been so inconsistent.
The Precursors: How Each One Reaches NAD+
Nicotinamide riboside (NR)
Nicotinamide riboside is the most extensively studied precursor in humans. It enters the salvage pathway one step ahead of nicotinamide, is orally bioavailable, and does not cause the flushing associated with niacin. Human trials have used doses from 250 mg to 2,000 mg daily, with 1,000 mg the most common research dose.
Nicotinamide mononucleotide (NMN)
NMN sits one step closer to NAD+ than NR does. Its regulatory status varies by country, and the human trial base is smaller than NR's, but it also raises blood NAD+ measurably.
Niacin and nicotinamide
The two classic B3 forms remain the cheapest and, in one specific clinical context, the best-evidenced. Niacin causes prostaglandin-mediated flushing at higher doses; nicotinamide (niacinamide) does not, and is the form used in most general-purpose formulas.
The methylation question
Excess nicotinamide is cleared by methylation, which consumes methyl groups donated by betaine (TMG) and folate. At the gram-level doses used in research, this has prompted a theoretical concern about methyl group depletion — the reason TMG is often sold alongside NAD+ precursors. It is a plausible mechanism, but human trials have not demonstrated clinically meaningful methyl depletion at typical supplemental doses, so this is a precaution rather than an established requirement.
What the Evidence Actually Shows
NAD+ declines with age in human tissue. Evidence level: Well-established. Measured directly in human skin and muscle and replicated across species and tissue types. The magnitude varies by tissue and by measurement method, and blood levels track tissue levels poorly, but the direction of the finding is not seriously disputed.
Oral precursors raise NAD+ in human blood. Evidence level: Well-established. Multiple randomised placebo-controlled trials confirm it. A crossover trial in adults aged 55–79 taking 1,000 mg NR daily for six weeks raised blood NAD+ by roughly 60% with good tolerability. Bioavailability itself is not the open question.
Precursors improve muscle function or metabolic health in healthy adults. Evidence level: Preliminary and largely negative. This is where the story breaks down. A trial giving aged men 1 g NR daily for three weeks raised the muscle NAD+ metabolome and produced an anti-inflammatory transcriptomic signature — but did not improve mitochondrial bioenergetics. A 12-week trial of 2 g NR daily in obese, insulin-resistant men found no improvement in insulin sensitivity, body composition or mitochondrial function. A critical 2023 review of 25 human NR trials concluded that clinically relevant effects have been few, and that the literature has a tendency to overstate what was found.
NAD+ repletion helps in specific clinical deficiency states. Evidence level: Promising. The strongest human result comes from adult-onset mitochondrial myopathy, where escalating niacin doses restored patients' muscle NAD+ to control levels and improved muscle strength and mitochondrial biogenesis over 10 months. A separate trial found NMN improved skeletal muscle insulin sensitivity in prediabetic women, though the result attracted methodological debate. The pattern suggests NAD+ boosting matters most where NAD+ is genuinely depleted.
NAD+ supplementation extends healthy lifespan in humans. Evidence level: Mechanistically plausible but untested. The sirtuin and mitochondrial biology is compelling and the rodent data are encouraging, but no human trial has been designed or run long enough to test lifespan or healthspan endpoints. Anyone claiming otherwise is extrapolating from mice.
How to Approach NAD+ Support Practically
Start with what depletes it
Before buying a precursor, it is worth reducing NAD+ demand. Chronic inflammation, poor sleep, excess alcohol, unmanaged metabolic dysfunction and high oxidative stress all increase NAD+ consumption through PARP and CD38 activity. These levers are free, well-evidenced, and address the actual driver of decline rather than trying to out-supply it.
Exercise is the best-evidenced NAD+ intervention
Endurance and resistance training both upregulate the salvage pathway enzyme NAMPT, the rate-limiting step in NAD+ recycling. Training also improves mitochondrial density through the same signalling pathways that sirtuins act on. If the goal is better cellular energy metabolism, structured exercise has a stronger and more consistent human evidence base than any NAD+ precursor.
If you supplement, be realistic about dose and expectations
Trial doses of NR have clustered around 250–1,000 mg daily. Most consumer products sit at the low end of that range, well below what the positive trials used. Expect a biomarker change rather than a felt effect; the honest summary of the healthy-adult literature is that people generally do not notice much. Give any trial at least 8–12 weeks and judge it on something measurable rather than on impression.
Support the surrounding pathway
Adequate B-vitamin status, particularly B2 and B6, supports the enzymes involved in NAD+ metabolism, and sufficient methyl donor intake from folate, B12 and choline-rich foods covers the methylation load. A varied diet handles this without additional products in most cases.
Safety and Who Should Be Cautious
NR has been well tolerated across trials at doses up to 2,000 mg daily for 12 weeks, with side effects — mild nausea, flushing, digestive upset — occurring at rates similar to placebo in most studies. Nicotinamide is likewise well tolerated at supplemental doses. Niacin at gram-level doses causes pronounced flushing and, in high-dose long-term use, has been associated with liver enzyme elevation and impaired glucose tolerance.
Long-term safety data beyond about a year are limited for all of these compounds. There is also an unresolved theoretical question about NAD+ availability and existing cancers, since rapidly dividing cells have high NAD+ demand — no human evidence of harm exists, but anyone with an active or recent cancer diagnosis should not supplement without oncology input.
ⓘ Speak to a doctor before using NAD+ precursors if you are pregnant or breastfeeding, have liver disease, have a history of cancer, take medication for diabetes or lipids, or are on any therapy where metabolic changes matter. High-dose niacin in particular interacts with statins and glucose-lowering drugs.
Frequently Asked Questions
Will taking an NAD+ supplement give me more energy?
Probably not in the way the word "energy" is usually marketed. NAD+ is essential for producing ATP, but in a healthy person the pathway is not the limiting factor — adding more precursor does not speed up a process that is not bottlenecked. Trials in healthy adults have generally not found improvements in fatigue, exercise capacity or mitochondrial output despite clear increases in blood NAD+.
Is NMN better than NR?
There is no good head-to-head human evidence establishing either as superior. NMN is one enzymatic step closer to NAD+, which sounds like an advantage, but it is a larger molecule and how it enters cells is still debated. NR has the deeper human trial base. Regulatory status also differs by market, which affects availability more than efficacy does.
Do I need to take TMG with NAD+ precursors?
It is a reasonable precaution at high doses rather than a proven necessity. The logic is sound — clearing excess nicotinamide consumes methyl groups — but human trials have not shown clinically significant methyl depletion at typical doses. If your diet includes adequate folate, B12 and choline, the need is likely minimal.
Can I raise NAD+ through food?
Only indirectly. Foods contain B3 in the form of niacin and nicotinamide — meat, fish, poultry, peanuts, mushrooms and whole grains are good sources — and your body builds NAD+ from these plus a small contribution from tryptophan. Dietary intake covers normal requirements comfortably, but you cannot reach research-level doses through food, and there is no evidence that you need to.
How long before NAD+ levels drop again if I stop?
Quickly. Blood NAD+ returns toward baseline within days to a couple of weeks after stopping supplementation, because the pool turns over continuously and is not stored. Any benefit is contingent on continued intake, which is worth factoring into the cost calculation.
Scientific References
- Massudi H, Grant R, Braidy N, Guest J, Farnsworth B, Guillemin GJ. "Age-Associated Changes in Oxidative Stress and NAD+ Metabolism in Human Tissue." PLOS ONE, 2012.
- Camacho-Pereira J, Tarragó MG, Chini CCS, et al. "CD38 Dictates Age-Related NAD Decline and Mitochondrial Dysfunction through an SIRT3-Dependent Mechanism." Cell Metabolism, 2016.
- Trammell SAJ, Schmidt MS, Weidemann BJ, et al. "Nicotinamide riboside is uniquely and orally bioavailable in mice and humans." Nature Communications, 2016.
- Martens CR, Denman BA, Mazzo MR, et al. "Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults." Nature Communications, 2018.
- Dollerup OL, Christensen B, Svart M, et al. "A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men: safety, insulin-sensitivity, and lipid-mobilizing effects." The American Journal of Clinical Nutrition, 2018.
- Elhassan YS, Kluckova K, Fletcher RS, et al. "Nicotinamide Riboside Augments the Aged Human Skeletal Muscle NAD+ Metabolome and Induces Transcriptomic and Anti-inflammatory Signatures." Cell Reports, 2019.
- Pirinen E, Auranen M, Khan NA, et al. "Niacin Cures Systemic NAD+ Deficiency and Improves Muscle Performance in Adult-Onset Mitochondrial Myopathy." Cell Metabolism, 2020.
- Yoshino M, Yoshino J, Kayser BD, et al. "Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women." Science, 2021.
- Vinten KT, Trętowicz MM, Coskun E, van Weeghel M, Cantó C, Zapata-Pérez R, Janssens GE, Houtkooper RH. "NAD+ precursor supplementation in human ageing: clinical evidence and challenges." Nature Metabolism, 2025.
Disclaimer
This article is provided for educational and informational purposes only and does not constitute medical advice, diagnosis or treatment. It is not intended to replace consultation with a qualified healthcare professional. Dietary supplements are not medicines and should not be used as a substitute for a varied, balanced diet and a healthy lifestyle. Individual needs vary, and no supplement is appropriate for everyone. Always consult your doctor or pharmacist before starting any new supplement, particularly if you are pregnant or breastfeeding, have an existing medical condition, or are taking prescription medication. LIVV100® makes no claim that any product diagnoses, treats, cures or prevents any disease.
